BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//MLSC - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MLSC
X-ORIGINAL-URL:https://www.masslifesciences.com
X-WR-CALDESC:Events for MLSC
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210923T103000
DTEND;TZID=America/New_York:20210923T113000
DTSTAMP:20260409T113827
CREATED:20210802T155845Z
LAST-MODIFIED:20210802T155845Z
UID:14380-1632393000-1632396600@www.masslifesciences.com
SUMMARY:Life Sciences Apprenticeship Launch
DESCRIPTION:Join us to celebrate the launch of the first Life Sciences Apprenticeship Program in Massachusetts\, providing candidates an alternative pathway to careers in biomanufacturing and clinical trials. This community event will introduce the first two cohorts of apprentices and highlight participating employers. We will also hear from key public officials committed to workforce development initiatives\, locally to nation wide. \nHonorary Remarks By:\nUnited States Secretary of Labor Marty Walsh\nMassachusetts Secretary of Labor and Workforce Development Rosalin Acosta\nRepresentative Lori Trahan\, Third District of Massachusetts \nGuest Remarks By:\nKenn Turner\, President and CEO\, Massachusetts Life Sciences Center\nKendalle Burlin O’Connell\, President and COO\, MassBio\nEmployer Partner – Bristol Myers Squibb\n2021 Apprentice Class Member \nAbout the Program\nThis unique program is registered with the state as an apprenticeship and provides candidates an alternative pathway into the life sciences industry. MassBioEd has focused on recruiting candidates from under-represented groups in the industry as well as unemployed and under-employed individuals. Through accelerated training\, apprentices will gain foundational knowledge\, industry-recognized skills\, and work experience\, providing them with career opportunities at sustainable wages. MassBioEd chose to target Biomanufacturing Technicians and Clinical Trial Associates for the first year of the apprenticeship program because of high employer demand for these occupations.
URL:https://www.masslifesciences.com/event/life-sciences-apprenticeship-launch/
LOCATION:Online\, online
ORGANIZER;CN="MassBioEd":MAILTO:communications@massbioed.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210922T160000
DTEND;TZID=America/New_York:20210922T190000
DTSTAMP:20260409T113827
CREATED:20210827T143049Z
LAST-MODIFIED:20210827T143049Z
UID:14527-1632326400-1632337200@www.masslifesciences.com
SUMMARY:Mini Golf for Good
DESCRIPTION:There is NOTHING quite like the Mini Golf for Good Tournament to benefit Life Science Cares! This fun and competitive event features three nine-hole mini-golf courses popping up in the middle of Tech Square\, with company teams putting for a variety of trophies. This party attracts 300+ employees of life science companies to enjoy the food trucks\, free beer\, lawn games\, raffle\, and crazy costumes of their peers. Don’t miss the drama as company teams compete for bragging rights in categories like Most Holes in One\, Best Outfits\, Best Team Names & Worst Score. Learn more and register at https://lifesciencecares.org/events/mini-golf-for-good. \nSeptember 22\, 2021\n4 p.m.-7 p.m.\n*Raindate: September 29\, 2021\nTech Square\, Cambridge
URL:https://www.masslifesciences.com/event/mini-golf-for-good/
LOCATION:MA
ORGANIZER;CN="Life Science Cares":MAILTO:info@lifesciencecares.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210917T083000
DTEND;TZID=America/New_York:20210917T160000
DTSTAMP:20260409T113827
CREATED:20210802T154831Z
LAST-MODIFIED:20210802T154831Z
UID:14361-1631867400-1631894400@www.masslifesciences.com
SUMMARY:Engineering the Next Wave of Immunotherapy
DESCRIPTION:Engineering the Next Wave of Immunotherapy\nFriday\, September 17\, 2021\n8:30 a.m. EDT on Zoom\nThe 19th Annual Koch Institute Summer Symposium will be held virtually on September 17\, 2021 and will focus on cancer immunotherapy. Register now (https://mit.zoom.us/webinar/register/WN_iD8S9uJRQZuzXxZG4Ef9uA). \nCancer immunotherapy has revolutionized the landscape of cancer treatment\, our thinking of tumor biology and clinical practice. Following the groundbreaking successes of checkpoint blockade therapy and CAR T cell therapy\, culminating in multiple FDA-approved treatments and the awarding of the 2018 Nobel Prize in Medicine to Jim Allison and Tasuku Honjo\, the field is currently at a critical juncture. \nWhile checkpoint blockade therapy has demonstrated that the immune system can be harnessed to fight cancer\, the next generation of treatments will require us to understand what causes resistance in non-responders\, how this can be overcome\, and how these issues are best addressed clinically. Discussing these questions will be at the core of this symposium as we move towards our ultimate goal to increase the number of patients benefiting from immunotherapy. \nSpeakers\nTargeting T Cells\nRafi Ahmed\, Michael Dougan\, Chris Love \nThinking Beyond T Cells\nYasmine Belkaid\, Juan Mendoza\, Stefani Spranger\, Lauren Zasadil \nEngineering Clinical Translation\nChris Garcia\, Juliana Idoyaga\, Crystal Mackall \nPanel Discussion: Clinical Translation: A Real Life Perspective\nDaniel Chen\, Michael Dougan\, Kimberly Shafer-Weaver\nModerators: Steven Silverstein\, Jane Wilkinson \nThank You to Our Sponsors\nAgilent Technologies\, Inc.\nDragonfly Therapeutics\, Inc.\nRepertoire Immune Medicines\nRibon Therapeutics\nSkyhawk Therapeutics
URL:https://www.masslifesciences.com/event/engineering-the-next-wave-of-immunotherapy/
LOCATION:Online\, online
ORGANIZER;CN="Koch Institute for Integrative Cancer Research at MIT":MAILTO:kievents@mit.edu
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210915T120000
DTEND;TZID=America/New_York:20210915T133000
DTSTAMP:20260409T113827
CREATED:20210827T142815Z
LAST-MODIFIED:20210827T142815Z
UID:14542-1631707200-1631712600@www.masslifesciences.com
SUMMARY:mRNA: The Future of Therapeutics
DESCRIPTION:2020 was the year that established mRNA as a household name around the globe. This previously unheard-of treatment option suddenly became the poster child as a way to end the COVID-19 pandemic. Both the Pfizer and Moderna COVID-19 vaccines contain mRNA that once injected\, encodes for the spike glycoprotein found on the surface of the virus. Since first discovered in 1961\, mRNA has emerged as a promising therapeutic medication to treat a host of other diseases including cancer\, heart disease\, autoimmune conditions\, and cystic fibrosis. Could the future eradication of such devastating diagnoses be as simple as receiving a unique sequence of nucleotides that encode for a specific protein? Hear from a handful of innovative scientists working at the forefront of developing these potentially life altering medications. \nJoin us for this discussion on the Clubhouse App.
URL:https://www.masslifesciences.com/event/mrna-the-future-of-therapeutics/
LOCATION:France
ORGANIZER;CN="Caldwell Intellectual Property Law":MAILTO:eyob@caldwellip.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210908
DTEND;VALUE=DATE:20210927
DTSTAMP:20260409T113827
CREATED:20210908T201738Z
LAST-MODIFIED:20210908T201738Z
UID:14600-1631059200-1632700799@www.masslifesciences.com
SUMMARY:UMass M2D2 Presents IMPACT: Work 1-on-1 with Investors from Boston Scientific & Asahi Intecc
DESCRIPTION:IMPACT is a 12-week accelerator program for life sciences startups that aims to help advance their innovations. Applications are officially open for Cycle 1 of the IMPACT Accelerator Program!\nAttend educational workshops\nAccess mentorship and resources needed for the commercialization of your idea\nIf your startup is chosen for the Cycle 1 Cohort\, you’ll pitch your solution to a panel of investors with the ability to have 1-on-1 meetings with experts from major corporations like Boston Scientific and Asahi Intecc! \nAPPLY BY SEPTEMBER 26th @ 11:59PM EST!
URL:https://www.masslifesciences.com/event/umass-m2d2-presents-impact-work-1-on-1-with-investors-from-boston-scientific-asahi-intecc/
LOCATION:MA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210825T160000
DTEND;TZID=America/New_York:20210825T190000
DTSTAMP:20260409T113827
CREATED:20210819T172640Z
LAST-MODIFIED:20210819T172640Z
UID:14411-1629907200-1629918000@www.masslifesciences.com
SUMMARY:Virtual BioXchange
DESCRIPTION:Miss being able to network with colleagues in the life science industry? We have you covered with the best virtual networking experience through Grapevine Network’s networking platform. Connect with life science colleagues from all over the world. \nBioXchange has gone virtual to allow the best online opportunity to interact with individuals from throughout the life science industry. The event will be hosted on Grapevine Network’s platform which provides an amazing experience that allows attendees the freedom to navigate between different group discussions within an interactive chatroom environment. The platform provides the closest experience to a live networking experience. \nParticipants are welcome to join the event at any point of time. The event is subject to run later than the posted end time as the room will stay open as long as people are actively engaged within the chat room. \n***Event is expected to sell out and NOT ALL RVSPS ARE GUARANTEED ENTRY into the event due to the limited attendee capacity offered on the platform.
URL:https://www.masslifesciences.com/event/virtual-bioxchange-5/
LOCATION:Online\, online
ORGANIZER;CN="BioXchange":MAILTO:bioxchange.boston@gmail.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210820T100000
DTEND;TZID=America/New_York:20210820T110000
DTSTAMP:20260409T113827
CREATED:20210809T154041Z
LAST-MODIFIED:20210809T154230Z
UID:14423-1629453600-1629457200@www.masslifesciences.com
SUMMARY:Info Session: Angel Investor Tax Credit Program
DESCRIPTION:Offered to investors interested in funding early-stage companies engaged in life sciences research and development\, commercialization\, and manufacturing in Massachusetts. \nWe are excited to inform you that the MLSC has launched the second round of the Angel Investor Tax Credit program\, which aims to encourage investments in gateway municipalities and throughout the Commonwealth. \nTwo deadlines are offered to apply:\n• October 29\, 2021\n• January 14\, 2022 \nJoin us to learn more about this exciting opportunity!
URL:https://www.masslifesciences.com/event/info-session-angel-investor-tax-credit-program/
LOCATION:Online\, online
ORGANIZER;CN="Institute for Applied Life Sciences":MAILTO:contactials@umass.edu
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210818T120000
DTEND;TZID=America/New_York:20210818T133000
DTSTAMP:20260409T113827
CREATED:20210805T230545Z
LAST-MODIFIED:20210805T231422Z
UID:14397-1629288000-1629293400@www.masslifesciences.com
SUMMARY:Project Onramp Showcase 2021
DESCRIPTION:Project Onramp creates paid summer internships for Massachusetts college students who are under-resourced and often first-generation\, helping to bridge the opportunity gap for these promising young people. \nJoin us virtually to celebrate the 128 students who make up the Class of 2021. Hear about what they’ve worked on\, the lessons they’ve learned\, and the professional networks they’ve created to help them consider careers in the life sciences. \nWednesday\, August 18th at 12 pm via Zoom \nFinal agenda and login information to come.
URL:https://www.masslifesciences.com/event/project-onramp-showcase-2021/
LOCATION:Online\, online
ORGANIZER;CN="Project Onramp":MAILTO:lila@lifesciencecares.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210817T110000
DTEND;TZID=America/New_York:20210817T120000
DTSTAMP:20260409T113827
CREATED:20210802T155043Z
LAST-MODIFIED:20210802T155043Z
UID:14359-1629198000-1629201600@www.masslifesciences.com
SUMMARY:Rare Disease Research in the United States: Understanding FDA Guidance and Flexibility in the Application of Regulatory Standards
DESCRIPTION:The Orphan Drug Act (ODA) defines a rare disease as a disease or condition that affects less than 200\,000 people in the United States.  Within this range we see conditions like sickle cell disease with a prevalence of over 100\,000\, down to rare genetic diseases that may occur in a handful of patients. As approaches to clinical development are constrained by issues of enrollment and statistical powering\, the categories defined by prevalence distribution (rare\, ultra-rare and uber-rare) require differing approaches within the framework of identical statutory standards for safety and efficacy. At the level of the ultra and uber-rare conditions that make up the majority of rare disease\, there is an unmet need not only for treatments but also for the tools to evaluate whether a given treatment works.\nThis webinar will focus on challenges and areas of flexibility within the application of the statutory standards as they apply to rare diseases. Particular attention will be paid not only to the laws and guidelines that specifically relate to orphan drugs but also how the general regulatory standards that govern safety and efficacy are uniquely applied to rare diseases at different levels of prevalence. \nThis webinar will cover rare disease research: \nCore challenges – knowledge of the disease\, clinical trial design and enrollment and others\nThe legal framework and guidance relevant to rare disease research with case studies focusing on the role of innovative clinical trial design\, Expanded Access data\, and the natural history studies in recent approvals\nStrategies specific to ultra- and uber-rare diseases
URL:https://www.masslifesciences.com/event/rare-disease-research-in-the-united-states-understanding-fda-guidance-and-flexibility-in-the-application-of-regulatory-standards/
LOCATION:Online\, online
ORGANIZER;CN="MMS Holdings":MAILTO:media@mmsholdings.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210802T080000
DTEND;TZID=America/New_York:20210917T230000
DTSTAMP:20260409T113827
CREATED:20210621T195946Z
LAST-MODIFIED:20210621T200047Z
UID:14102-1627891200-1631919600@www.masslifesciences.com
SUMMARY:Foundations in Quality for the Life Sciences
DESCRIPTION:Quality is critically important to the success of Life Sciences companies. The Foundations in Quality for the Life Sciences Industry provides presents concepts\, tools and techniques for real world\, on‐the‐job application of quality that is practical for a wide range of organizations. It is targeted for the application of quality in life sciences\, including\, but not limited to: biotechnology\, pharmaceuticals\, biomedical\ntechnologies\, life systems technologies\, nutraceuticals\, cosmeceuticals\, food processing\, environmental\, biomedical devices\, and organizations and institutions that devote the majority of their efforts in the various stages of research\, development\, clinical trials\, manufacturing\, supply chain management\, project management\, technology transfer and commercialization. \nThis course provides an insight into the mindset of Quality along with an overview the concepts\, principles and processes/activities involved in Quality Assurance\, Quality Control\, and Regulatory Compliance within the Life Sciences Industry. Emphasis will be placed on understanding the “business of Biotech; the remit of Global Regulatory Agencies and principles/processes for establishing and enforcing regulation and guidance; Quality management systems\, operations and compliance; Quality leadership; Quality Planning; and Careers in the Quality profession. Students will be exposed to a variety of industry experts during the course. Emphasis will also be placed on current Good Manufacturing Practices\, Good Laboratory Practices and Good Clinical Practices. Students will gain a practical knowledge of Quality as a scientific discipline.
URL:https://www.masslifesciences.com/event/foundations-in-quality-for-the-life-sciences-2/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210728T160000
DTEND;TZID=America/New_York:20210728T190000
DTSTAMP:20260409T113827
CREATED:20210719T135537Z
LAST-MODIFIED:20210719T135537Z
UID:14303-1627488000-1627498800@www.masslifesciences.com
SUMMARY:Virtual BioXchange
DESCRIPTION:Miss being able to network with colleagues in the life science industry? We have you covered with the best virtual networking experience through Grapevine Network’s networking platform. Connect with life science colleagues from all over the world. \nBioXchange has gone virtual to allow the best online opportunity to interact with individuals from throughout the life science industry. The event will be hosted on Grapevine Network’s platform which provides an amazing experience that allows attendees the freedom to navigate between different group discussions within an interactive chatroom environment. The platform provides the closest experience to a live networking experience. \nParticipants are welcome to join the event at any point of time. The event is subject to run later than the posted end time as the room will stay open as long as people are actively engaged within the chat room. \n***Event is expected to sell out and NOT ALL RVSPS ARE GUARANTEED ENTRY into the event due to the limited attendee capacity offered on the platform.
URL:https://www.masslifesciences.com/event/virtual-bioxchange-4/
LOCATION:Online\, online
ORGANIZER;CN="BioXchange":MAILTO:bioxchange.boston@gmail.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210728T100000
DTEND;TZID=America/New_York:20210728T110000
DTSTAMP:20260409T113827
CREATED:20210713T123546Z
LAST-MODIFIED:20210713T123546Z
UID:14216-1627466400-1627470000@www.masslifesciences.com
SUMMARY:What can AI learn from our own brains? Bridging the gap between biology and code
DESCRIPTION:AI grows ever more powerful and ubiquitous\, powered by vast sources of data and inexpensive cloud processing power. Yet the human brain\, using just 25W of power and 6 kHz neuron speed\, remains many orders more efficient than current AI processing approaches. Leveraging insights from new optical and physiological recording techniques\, Prof. Bart M. ter Haar Romeny will help bridge the gap between AI and how the human brain processes sight\, giving practical applications with respect to computer vision and machine learning\, especially in medical image analysis such as neuroimaging that can help accelerate neurology research\, clinical trials and care delivery. \nA 30 minute lecture by Em.Prof. Romeny will be followed by a chat with his former students\, Vesna Prčkovska\, CEO\, and Paulo Rodriguez\, CTO of QMENTA. Please bring your questions for our closing Q&A. Zoom space is limited\, so reserve your place today. \nKey Takeaways:\n– How we can bridge the gap between biological and AI communities\n– New optical and physiological recording techniques in imaging analysis\n– Practical applications with respect to computer vision and machine learning \nProf. Bart M. ter Haar Romeny is emeritus professor in Biomedical Image Analysis at Eindhoven University of Technology in the Netherlands. He obtained his MSc in Applied Physics from Delft University of Technology and PhD from Utrecht University. \nHe worked his whole career on biologically inspired medical image analysis algorithms\, especially for computer-aided diagnosis (cancer\, heart\, brain\, diabetes)\, image guided neurosurgery and visualization of brain connectivity from MRI diffusion tensor imaging. He initiated and led the RetinaCheck project\, a large international AI-based retinal image screening program for diabetes. He published over 250 papers\, 12 books and book chapters\, and 3 patents. He teaches a national PhD course on the neuro-mathematics of deep learning and human visual perception.
URL:https://www.masslifesciences.com/event/what-can-ai-learn-from-our-own-brains-bridging-the-gap-between-biology-and-code/
LOCATION:Online\, online
ORGANIZER;CN="QMENTA":MAILTO:info@qmenta.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210727T170000
DTEND;TZID=America/New_York:20210807T170000
DTSTAMP:20260409T113827
CREATED:20210713T123813Z
LAST-MODIFIED:20210713T123837Z
UID:14213-1627405200-1628355600@www.masslifesciences.com
SUMMARY:Open Enrollment Program Leading Digital Transformation in Health Care
DESCRIPTION:This Harvard Medical School online program provides you with the knowledge\, tools and strategies to design and implement technology-enabled change initiatives in health care. It will feature a combination of live virtual class sessions and self-paced learning and discussions. A certificate of completion will be provided.
URL:https://www.masslifesciences.com/event/open-enrollment-program-leading-digital-transformation-in-health-care/
LOCATION:Virtual
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210722T160000
DTEND;TZID=America/New_York:20210722T180000
DTSTAMP:20260409T113827
CREATED:20210527T143823Z
LAST-MODIFIED:20210527T143823Z
UID:13974-1626969600-1626976800@www.masslifesciences.com
SUMMARY:The Big Pitch VIRTUAL COMPETITION
DESCRIPTION:The Big Pitch is a virtual quick pitch competition for the most promising biotech startups in the US. This series challenges all-stars from 3 regions—West\, South and Northeast—to score points with investor judges for their treatment\, technology or therapy. The winning startup from each region will win the grand prize and bragging rights. \nFeatures the top life science startups from the West\, South and Northeast regions in the US\nStartups apply and two entrepreneurs per region will be selected by an advisory board\nSeven-minute live pitches followed by a 5 min Q&A with VC judges\nWinners are selected by a panel of investors and the LaunchBio community
URL:https://www.masslifesciences.com/event/the-big-pitch-virtual-competition/
LOCATION:Online\, online
ORGANIZER;CN="LaunchBio":MAILTO:joan@launchbio.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210722T083000
DTEND;TZID=America/New_York:20210722T153000
DTSTAMP:20260409T113827
CREATED:20210621T200527Z
LAST-MODIFIED:20210621T200635Z
UID:14031-1626942600-1626967800@www.masslifesciences.com
SUMMARY:MALSI+2021 The Hub at Warp Speed: From Lab to Jab to Beyond
DESCRIPTION:The 14th Annual Massachusetts Life Sciences Innovation (MALSI+) Day is the biggest day for life sciences startups and innovation in the Commonwealth. MALSI+ 2021 is a hands-on event which brings together scientists\, post-docs\, professors\, entrepreneurs\, innovators\, and venture capitalists. The event features a keynote by Barbara Fox\, CEO of Rheos Medicines; pharmaceutical innovation and investor perspective panels; an innovators’ marketplace; poster competition with prizes; 1:1 curated connections and networking on the Goldcast platform. The day is filled with networking opportunities. Don’t miss it!
URL:https://www.masslifesciences.com/event/malsi2021-the-hub-at-warp-speed-from-lab-to-jab-to-beyond/
LOCATION:Online\, online
ORGANIZER;CN="MassVentures":MAILTO:mwilcox@mass-ventures.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210715T120000
DTEND;TZID=America/New_York:20210715T130000
DTSTAMP:20260409T113827
CREATED:20210621T200123Z
LAST-MODIFIED:20210621T200123Z
UID:14090-1626350400-1626354000@www.masslifesciences.com
SUMMARY:How to Tell Your Innovation's Amazing Story
DESCRIPTION:How can you cut through the noise and help potential partners and investors understand what makes your product special\, innovative\, and worth a closer look? \nInvestors\, journalists\, and the general public are awash in information overload. Join Joshua Gunn\, founder of Cambridge\, MA-based creative studio Planet Nutshell\, for a session on how you can easily use the power of video to explain what you do and amplify the message of your company or idea. \nIt’s all about your story.\nWe see it in the most compelling\, successful pitches at M2D2 events like Barracuda Bowl and the $200K Challenge: It’s the personal stories behind the innovations that make potential investors and strategic partners prick up their ears and want to learn more. Tell your story on video and suddenly it becomes visually captivating\, more memorable\, and highly sharable. \nJosh will reveal insights from more than a decade of working with biotech and healthcare companies of all sizes\, from fledgling startups to big corporations. We’ll explore the one thing that holds true for all of them: The importance and power of telling a great story.
URL:https://www.masslifesciences.com/event/how-to-tell-your-innovations-amazing-story/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210712T120000
DTEND;TZID=America/New_York:20210712T123000
DTSTAMP:20260409T113827
CREATED:20210621T201119Z
LAST-MODIFIED:20210621T201119Z
UID:14002-1626091200-1626093000@www.masslifesciences.com
SUMMARY:Clinical Trials: Patients as Research Partners
DESCRIPTION:In this Harvard Medical School special event\, Linnea Olson\, a patient advocate\, activist\, blogger and artist\, will share her remarkable journey as a participant in six phase I clinical trials for ALK-mutant non-small cell lung cancer (NSCLC) – three of which led to FDA approval of new targeted therapies. Linnea will be joined by two senior drug development leaders whose therapies have played such an important part in her story. Join us for a wide-ranging discussion on patient-centric drug discovery and development\, exciting advances in cancer treatments\, and living with cancer.
URL:https://www.masslifesciences.com/event/clinical-trials-patients-as-research-partners/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210630T090000
DTEND;TZID=America/New_York:20210630T113000
DTSTAMP:20260409T113827
CREATED:20210621T200554Z
LAST-MODIFIED:20210621T200727Z
UID:14015-1625043600-1625052600@www.masslifesciences.com
SUMMARY:Neuroimmunology: Potential for Novel Therapeutics for CNS Disorders
DESCRIPTION:On June 30th \, Johnson & Johnson Innovation will host a virtual scientific event on state-of-the-art developments in neuroimmunology\, bringing together entrepreneurs\, start-ups\, researchers\, and scientists from across Europe and beyond. Learn more and register today
URL:https://www.masslifesciences.com/event/neuroimmunology-potential-for-novel-therapeutics-for-cns-disorders/
LOCATION:Online\, online
ORGANIZER;CN="Johnson & Johnson Innovation":MAILTO:clee22@its.jnj.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210624T123000
DTEND;TZID=America/New_York:20210624T133000
DTSTAMP:20260409T113827
CREATED:20210621T200314Z
LAST-MODIFIED:20210621T200344Z
UID:14049-1624537800-1624541400@www.masslifesciences.com
SUMMARY:BARDA Mask Innovation Challenge Awards Ceremony
DESCRIPTION:The Biomedical Advanced Research & Development Authority’s Division of Research\, Innovation\, & Ventures (BARDA DRIVe)\, in partnership with the National Institute for Occupational Safety and Health (NIOSH)\, is proud to present the Awards Ceremony for the “Mask Innovation Challenge: Building Tomorrow’s Mask.” \nThis event will celebrate our 10 Phase 1 finalist teams. They’ve all been working tirelessly to answer the PPE challenge of the pandemic era: Re-imagining and creating the mask of the future. \nWe are proud to announce these winners and highlight our partners and supporters in BARDA’s first-ever Challenge Competition. See you there!
URL:https://www.masslifesciences.com/event/barda-mask-innovation-challenge-awards-ceremony/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210623T160000
DTEND;TZID=America/New_York:20210623T190000
DTSTAMP:20260409T113827
CREATED:20210621T200258Z
LAST-MODIFIED:20210621T200258Z
UID:14050-1624464000-1624474800@www.masslifesciences.com
SUMMARY:Venture Capital 101
DESCRIPTION:If you are interested in learning more about how VC investing works\, what their process is for engaging with a life science startup\, and how they manage their portfolios; then you will not want to miss our next event. Please join us on June 23rd from 4-5PM EDT for a talk with Riley Rodgers from Valia Ventures as he explains the ins and outs of VC investing followed by open networking from 5-7PM EDT via the Grapevine Network. \nParticipants are welcome to join the event at any point of time. The event is subject to run later than the posted end time as the room will stay open as long as people are actively engaged within the chat room. \n***Event is expected to sell out and NOT ALL RVSPS ARE GUARANTEED ENTRY into the event due to the limited attendee capacity offered on the platform.
URL:https://www.masslifesciences.com/event/venture-capital-101/
LOCATION:Online\, online
ORGANIZER;CN="BioXchange":MAILTO:bioxchange.boston@gmail.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210623T110000
DTEND;TZID=America/New_York:20210623T120000
DTSTAMP:20260409T113827
CREATED:20210621T200807Z
LAST-MODIFIED:20210621T200807Z
UID:14014-1624446000-1624449600@www.masslifesciences.com
SUMMARY:The Entrepreneurial Way: Veterans Lead in Business & Beyond
DESCRIPTION:Join Johnson & Johnson Innovation on June 23rd for a conversation with leaders from the Johnson & Johnson Family of Companies\, Bunker Labs\, and other experts in the field to discuss the state of Veteran entrepreneurship and the potential impact on healthcare and beyond. \nWe’ll also share details about the Veterans Lead QuickFire Challenge series which is offering grant funding and mentorship opportunities for Veteran entrepreneurs in health care.
URL:https://www.masslifesciences.com/event/the-entrepreneurial-way-veterans-lead-in-business-beyond/
LOCATION:Virtual Event
ORGANIZER;CN="Johnson & Johnson Innovation":MAILTO:clee22@its.jnj.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210622T110000
DTEND;TZID=America/New_York:20210622T123000
DTSTAMP:20260409T113827
CREATED:20210621T200823Z
LAST-MODIFIED:20210621T200823Z
UID:14013-1624359600-1624365000@www.masslifesciences.com
SUMMARY:Digital Therapeutics and the Future of Medicine
DESCRIPTION:With healthcare becoming more digital\, especially over the past year\, innovators are continuing to demonstrate the power of these potential solutions. However\, despite the constant growth in the last decade and the surge in innovations in the past year\, there are still significant challenges in the path to success for these solutions. \nJoin Johnson & Johnson Innovation – JLABS on June 22nd as they welcome experts in the space to discuss the opportunities and challenges of potential digital solutions from a variety of perspectives\, and how large players in the ecosystem are looking towards the future.
URL:https://www.masslifesciences.com/event/digital-therapeutics-and-the-future-of-medicine/
LOCATION:Online\, online
ORGANIZER;CN="Johnson & Johnson Innovation":MAILTO:clee22@its.jnj.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210618
DTEND;VALUE=DATE:20210619
DTSTAMP:20260409T113827
CREATED:20210423T202149Z
LAST-MODIFIED:20210423T202149Z
UID:13795-1623974400-1624060799@www.masslifesciences.com
SUMMARY:VISTA: A New Immune Checkpoint in Cancer\, Autoimmunity and Beyond
DESCRIPTION:Virtual symposium June 18\, 2021. Hosted by Randolph Noelle\, Ph.D. and Padmanee Sharma\, M.D.\, Ph.D. \nSymposium Agenda \nVISTA function across multiple immune lineages in the normal immune system\nVISTA regulation of the tumor microenvironment in human cancer\nDiscovery of anti-VISTA antibodies\nClinical development of anti-VISTA antibodies for cancer immunotherapy\nVISTA counterreceptors \nOrganized by Curis\, Inc.
URL:https://www.masslifesciences.com/event/vista-a-new-immune-checkpoint-in-cancer-autoimmunity-and-beyond/
LOCATION:Online\, online
ORGANIZER;CN="Curis%2C Inc.":MAILTO:info@curis.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210617T090000
DTEND;TZID=America/New_York:20210617T120000
DTSTAMP:20260409T113827
CREATED:20210511T202804Z
LAST-MODIFIED:20210511T202804Z
UID:13818-1623920400-1623931200@www.masslifesciences.com
SUMMARY:2021 CAPCaT Big Company/Little Company Showcase
DESCRIPTION:For the second straight year\, The Center for Advancing Point of Care Technologies (CAPCaT) in Heart\, Lung\, Blood\, and Sleep Disorders is pleased to present this high-energy\, high-value event for life sciences startups. Join us and open the doors to big company/little company strategic partnerships and grant funding opportunities. \nThe Agenda: \nI. Live pitch presentations to our panel of influential strategic and venture capital investors from 9 startups that received grant funding from CAPCaT in 2020: \nCardio Sounds – Device to provide heart and lung predictive clinical intelligence\nCase Western University – Anemia and hemoglobin test\nCognita Labs – CareCOPD precision care platform\nDaxor Corporation – Smart POC heart failure diuretic dosing\nEmerald Innovations – Remote monitoring solution for breathing\, sleep\, mobility\nGE Research – Bedside EIT Lung V/Q scanning\nLeuko Labs 2018 M2D2 $200K Challenge Winner – Non-invasive device to monitor and assess neutrophil levels\nNYU – RELAXaHEAD for Migraine+Sleep\nUSC – Coagulation Companion for Kids\nII. A panel presentation specifically aimed at preparing startups for strategic\, “big company/little company” partnerships. These industry influencers will share real examples and explain the how\, what\, why\, when\, and where of strategic partnerships—and you’re encouraged to participate via our online Q&A portal. \nIII. A presentation on small business funding opportunities and business programming available from the NIH.
URL:https://www.masslifesciences.com/event/2021-capcat-big-company-little-company-showcase-2/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210617T090000
DTEND;TZID=America/New_York:20210617T120000
DTSTAMP:20260409T113827
CREATED:20210423T202219Z
LAST-MODIFIED:20210423T202219Z
UID:13794-1623920400-1623931200@www.masslifesciences.com
SUMMARY:2021 CAPCaT Big Company/Little Company Showcase
DESCRIPTION:See 9 breakthrough point-of-care innovations and learn about strategic partnership and grant opportunities that can accelerate YOUR startup. \nFor the second straight year\, The Center for Advancing Point of Care Technologies (CAPCaT) in Heart\, Lung\, Blood\, and Sleep Disorders is pleased to present this high-energy\, high-value event for life sciences startups. Join M2D2 and open the doors to big company/little company strategic partnerships and grant funding opportunities. \nKEYNOTE SPEAKER: Bruce J. Tromberg\, PhD\nDr. Tromberg is the Director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) at the National Institutes of Health (NIH). He oversees a portfolio of research programs focused on developing\, translating\, and commercializing engineering\, physical science\, and computational technologies in Biology and Medicine.
URL:https://www.masslifesciences.com/event/2021-capcat-big-company-little-company-showcase/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210617T040000
DTEND;TZID=America/New_York:20210617T173000
DTSTAMP:20260409T113827
CREATED:20210527T143921Z
LAST-MODIFIED:20210527T143921Z
UID:13973-1623902400-1623951000@www.masslifesciences.com
SUMMARY:FOUNDERS CIRCLE: HOW TO RELOCATE YOUR EARLY-STAGE BIOTECH
DESCRIPTION:Your science is promising and your company is growing. Now is the time to envision your future workplace and consider making some moves. The real estate market can be frustrating\, and life science companies have special operational needs and regulations\, and financial limitations. This forum will explore real-life examples of successful and unsuccessful moves\, providing practical strategies to overcome the common pitfalls that complicate the relocation process. Facilitated by Explora BioLabs CEO\, Nathaniel “Sandy” Paige\, as well as other top experts in life science real estate who will discuss: \n-When and how to find your next space\n-Upfront work: needs analysis\, financial analysis\, market analysis\n-Tapping into City resources\n-Negotiating the terms of your lease\n-Realistic expectations for timelines and budget
URL:https://www.masslifesciences.com/event/founders-circle-how-to-relocate-your-early-stage-biotech/
LOCATION:Online\, online
ORGANIZER;CN="LaunchBio":MAILTO:joan@launchbio.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210616T183000
DTEND;TZID=America/New_York:20210616T193000
DTSTAMP:20260409T113827
CREATED:20210409T184630Z
LAST-MODIFIED:20210409T184713Z
UID:13691-1623868200-1623871800@www.masslifesciences.com
SUMMARY:A Foot in Both Worlds
DESCRIPTION:The MIT Koch Institute Clinical Investigator program offers physician-scientists a unique opportunity to participate in cutting-edge cancer research while continuing their medical practice and provides Koch Institute researchers with a frontline view of challenges in cancer treatment. This roundtable discussion with past and present Clinical Investigators explores the relationship between laboratory benchwork and clinical translation and practice. \nFeatured Presenters: \nScott Floyd\, MD\, PhD\nGary Hock and Lyn Proctor Associate Professor of Radiation Oncology\, Duke University\nAssistant Research Professor in Pharmacology and Cancer Biology\, Duke University Cancer Center \nSalil Garg\, MD\, PhD\nCharles W. (1955) and Jennifer C. Johnson Clinical Investigator\, Koch Institute\nPathologist\, Massachusetts General Hospital \nHojun Li\, MD\, PhD\nCharles W. (1955) and Jennifer C. Johnson Clinical Investigator\, Koch Institute\nAttending Physician\, Dana Farber/Boston Children’s Hospital Cancer and Blood Disorders Center \nAlice Tsang Shaw\, MD\, PhD\nGlobal Head of Translational Clinical Oncology\, Novartis\nAttending Physician\, Center for Thoracic Cancers\, Massachusetts General Hospital \nModerated by Michael B. Yaffe\, MD\, PhD\, Director\, KI Clinical Investigator Program\, David H. Koch Professor of Science\, Professor of Biology and Biological Engineering
URL:https://www.masslifesciences.com/event/with-in-sight-webinar-a-foot-in-both-worlds/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210616T130000
DTEND;TZID=America/New_York:20210616T140000
DTSTAMP:20260409T113827
CREATED:20210527T143939Z
LAST-MODIFIED:20210527T143939Z
UID:13972-1623848400-1623852000@www.masslifesciences.com
SUMMARY:LET'S TALK ABOUT: MODELING BEHAVIOR Examining DEI in Life Sciences
DESCRIPTION:One year ago\, the Death of George Floyd sparked a worldwide movement for racial equality and justice. There was an outcry of support from corporates and startups alike. There were press releases and social posts advocating for diversity\, equity\, inclusion—and industry-wide change. This month Let’s Talk About will examine how the life science industry has changed\, how companies have approached DEI initiatives\, and what start-ups can do to make their work culture inclusive.
URL:https://www.masslifesciences.com/event/lets-talk-about-modeling-behavior-examining-dei-in-life-sciences/
LOCATION:Online\, online
ORGANIZER;CN="LaunchBio":MAILTO:joan@launchbio.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210615T120000
DTEND;TZID=America/New_York:20210615T133000
DTSTAMP:20260409T113827
CREATED:20210510T195846Z
LAST-MODIFIED:20210510T195846Z
UID:13888-1623758400-1623763800@www.masslifesciences.com
SUMMARY:Clinical Trial Program Series - KEY CONSIDERATIONS & BEST PRACTICES
DESCRIPTION:Overview \nThis program is a series of 3 panel discussions with industry and government partners\, focused on providing high-level insight into the clinical trial process. Each event will have its own specific focus while contributing to a sequential flow for the series. Experts from varying backgrounds have been selected for each discussion to help provide a more robust and complete overview of key considerations and event topics for each discussion.\nGoal \nThis program aims to provide early-stage startups\, stakeholders\, and others\, with expert insight and knowledge into the clinical trial process. From attending these discussions\, attendees should have a better understanding of clinical trials\, the necessary steps needed to develop a plan that will lead to successful study outcomes\, insight into key considerations for the process\, and a better understanding of what partners to engage with\, and when.\nAgenda \n12:00pm – 12:30pm: Opening Remarks \n12:05pm – 12:10pm: Panelist Introductions \n12:10pm – 1:10pm: Panel Discussion \n1:10pm – 1:25pm: Q&A \n1:25pm – 1:30pm: Closing Remarks\nTopics \nClinical Trial Basics – Understanding your product\, Designing Your Study\, Regulatory Requirements and EC/IRB and Informed Consent\nSite selection\nMedical Device vs. Therapeutic\nDeveloping an MVP and manufacturing a product for studies\nThe importance of strategy and planning \nPanelists \nBarry Sands – President & Founder\, RQMIS\, Inc. \nRQMIS President and Founder\, Barry E. Sands\, is a Biomedical Engineer (with a chemical engineering specialization) by trade with a passion for helping medical companies get their products to market. Barry has seven years’ experience as a Biomedical Engineer and Sr. Scientific Reviewer at FDA/CDRH/ODE and FDA’s Boston District. This government experience was followed with seventeen years in midlevel and executive management positions in small start-up and large multinational medical device companies. Market responsibilities included United States (including Puerto Rico)\, European Union\, South America\, Middle East\, Canada\, Japan and South Korea. \nHe has provided companies with regulatory and clinical strategic advice on bringing novel technologies for both the pediatric and adult populations specially to the United States and EU markets. The devices involved have included wearable devices\, human tissue\, combination products\, electromechanical\, PPE\, ultrasonic imaging and PACS products. He has worked on various innovative medical devices including writing an FDA Presubmission for an electromechanical medical device with software that was used to diagnose radiation exposure. Barry was the primary author of the IDE for an electromechanical device with software that used irreversible electroporation used to treat Stage III Pancreatic Cancer. \nBarry has managed data management services designed to make the process of designing\, collecting\, reconciling and reviewing clinical research data more efficient and reliable. He has extensive knowledge of clinical data and biostatistics\, thus leading groups to make the use of EDC technology and the surrounding processes work to ensure the integrity of each data set. By minimizing the risks associated with EDC and clinical data management\, clean and accurate clinical research data is captured while meeting aggressive key project deadlines. Being for the sponsors\, less training time for each project and more time performing efficient tests. Within this point\, the role played by Barry is key to the successful planning and execution of a development program. \nHe has worked with different companies throughout his career path to accompany new projects developments\, in conjunction with the steps for having the facilities aligned to the worldwide regulations\, especially in QMS\, Manufacturing Operations & SupplyManagement. During these projects\, Barry is deeply involved in all the manufacturing activities\, managing and training people under the latest regulations. His QMS/Manufacturing experience has included the establishment of clean rooms for the packaging of sterile implants. Products manufactured in the QMS that Barry has designed/managed have included a wide range of complexity from soft bracing products to sterile active implantable products. \nBarry is currently serving as the Executive Regulatory Manager for a client that is working on developing an electronically-determined test for stroke that employs both AI and Machine Learning algorithms. In this role he guides all regulatory and quality decisions in related to product development. RQMIS is also currently developing a regulatory strategy and Presubmission to the FDA for a company developing a wearable patch that will detect biomarkers in a patient’s sweat using AI and machine learning technology. Similarly\, our team is working on generating a regulatory strategy for certification and testing standards required for masks for the FDA\, European NB and MHRA. \nHe is the CAPCaT reviewer responsible for reviewing/grading medical device grant applications to support development\, deployment\, and testing of promising “late-stage” point of care technologies that can be rapidly deployed to enhance the diagnosis\, monitoring\, management\, and/or treatment of heart\, lung\, blood or sleep disorders (NHLBI)\, with an additional interest in projects that incorporate complementary and integrative health approaches (NCCIH). \nBarry has managed FDA inspections in R&D facilities (including clinical study files) and manufacturing facilities located in the United States\, Germany and Japan. These inspections have included Level 1 (Abbreviated)\, Level 2 (Comprehensive)\, Level 3 (Compliance Follow‐up)\, For Cause\, Sterilization processes\, MDR/MedWatch\, Corrections and Removals Practices\, and Biomonitoring/Good Clinical Practices. Barry has designed/implemented corrective actions to resolve 483s\, Warning Letters\, and import detentions. \nAnn Han – Clinical Research Navigator\, University of Massachusetts Medical School \nAnn Han is the Clinical Research Navigator at UMass Medical where she works to connect researchers to resources to improve the efficiency and quality of clinical research. She facilitates clinical trial site selection activities and assists with clinical trial feasibility and recruitment and retention. She is a UMass CCTS Point of Contact for the Trial Innovation Network and a member of the CCTS and COVID research protocol review committees. She received her Master of Science in Health Services Research from Boston University and has over 15 years’ experience in clinical research. \nMelinda Hamer – Director of the Clinical Trials Center\, Walter Reed Army Institute of Research \nMelinda Morton Hamer MD\, MPH was the Director of the Clinical Trials Center at the Walter Reed Army Institute of Research from 2017-2021\, and is currently detailed to the Department of Health and Human Services\, Biomedical Advanced Research and Development Authority as a Senior Medical Advisor. She has served as a principal and associate investigator for more than 20 FDA regulated and other clinical trials\, to include multiple first-in-human vaccine trials\, and the largest in history controlled human malaria challenge trial\, and managed an annual budget of more than $10 million. She was principal investigator of the recently completed first-in-human trial of a novel Marburg virus vaccine\, in collaboration with the NIH’s Vaccine Research Center\, and served as an investigator on multiple COVID-19 related clinical trials. She is a U.S. Army flight surgeon and board-certified emergency physician\, and an Associate Professor in the Department of Military and Emergency \nMedicine at the Uniformed Services University of the Health Sciences in Bethesda\, Maryland. She also holds a part-time appointment as an Assistant Professor in the Department of Emergency Medicine at the George Washington University Department of Emergency Medicine. Dr. Hamer is also the co-author of official U.S. Government and Institute of Medicine reports on health care reconstruction efforts in Iraq\, and has over 40 peer-reviewed publications as well as dozens of national abstract presentations and other reports. \nMeg Johnson – Senior Manager of Clinical Research Compliance\, University of Massachusetts Medical School \nMeg Johnson has overseen the Office of Clinical Research for UMass Medical for the past 8 years. Prior to UMass Medical she worked in IRB Operations and Research for Harvard Medical School and Ohio State University. Meg received her BS in Health Policy and Administration from Penn State and her JD in Law from Ohio State University. \nGustavo Cipolla – Associate Director of Preclinical at Ethicon\, Johnson & Johnson \nInterventionalist & Scientist D.V.M. with extensive experience and expertise in the areas of preclinical research\, operation of preclinical research labs\, IACUC\, physician training\, FDA submissions and GLP compliance. Excellent track record in developing and implementing target specific preclinical research studies. Proven adaptation to different working environments (academic institutions\, start ups\, established corporations and contract research organizations) \nSpecialties: Operations\, Execution\, Compliance\, IACUC\, GLP \nModerator: Eric Claude – Vice President of Product Development\, MPR Associates\, Inc. \nEric Claude is the Vice President of MPR’s Health and Life Science practice. Mr. Claude has a background in engineering and a broad systems perspective in product design. With more than 25 years in the medtech industry\, Mr. Claude’s leadership and experience helps teams navigate the complex challenges in developing and commercializing breakthrough products. He has a passion for developing high performance multi-disciplinary teams and a focus on optimizing the new product development process to best manage risk and minimize time to market. MPR’s clients\, including companies large and small\, rely on Mr. Claude to be a valued senior advisor and executive sponsor for critical projects.
URL:https://www.masslifesciences.com/event/clinical-trial-program-series-key-considerations-best-practices/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210615T110000
DTEND;TZID=America/New_York:20210624T140000
DTSTAMP:20260409T113827
CREATED:20210409T185029Z
LAST-MODIFIED:20210409T185029Z
UID:13686-1623754800-1624543200@www.masslifesciences.com
SUMMARY:Designing and Implementing AI Solutions for Health Care
DESCRIPTION:Applications of artificial intelligence in health care are expanding rapidly. Despite its great long-term potential\, risks and challenges remain for both AI developers and their partners in health care\, the life sciences industry and digital health. \nThis program will allow leaders across the ecosystem to gain insights into what it takes to successful utilize AI in the unique cultural\, economic and regulatory context of health care. Interactive sessions will address technical concepts as well as real-world implementation\, with examples drawn from health care delivery/operations and drug development. \nThe curriculum will feature a combination of live virtual class sessions\, small group application exercises\, pre-work and vigorous discussions. Upon completion of the program\, participants will be able to immediately apply insights gained to the fast-moving and complex health care sector. A certificate of completion will be provided.
URL:https://www.masslifesciences.com/event/designing-and-implementing-ai-solutions-for-health-care/
LOCATION:Harvard Medical School\, 25 Shattuck St\, Boston\, 02115\, United States
ORGANIZER;CN="Harvard Medical School External Education":MAILTO:sqil@hms.harvard.edu
END:VEVENT
END:VCALENDAR